Ribbon Acquisition Corp. (RIBB) - 10-Q Summary
Business Context and Reporting Period
Ribbon Acquisition Corp. is a Cayman Islands exempted company and a "blank check" SPAC incorporated on July 17, 2024. The company completed its Initial Public Offering (IPO) on January 16, 2025, raising $50 million. As of the reporting period ended March 31, 2026, the company has not commenced operations and is focused on consummating a business combination. On June 30, 2025, the company entered into a Business Combination Agreement with DRC Medicine Inc., a Japanese company specializing in AI-powered diagnostic kits and protective masks.
Key Financial Metrics (Three Months Ended March 31, 2026)
| Metric | Value |
|---|---|
| Net Income | $252,755 |
| Operating Expenses | $77,786 |
| Trust Account Balance | $37,716,530 |
| Cash (Outside Trust) | $1,878 |
| Working Capital Deficit | ($1,008,960) |
| Accumulated Deficit | ($355,267) |
| Shares Subject to Redemption | 3,563,133 |
Material Changes vs. Prior Period
- Redemptions: In connection with a shareholder meeting on January 9, 2026, to approve an extension of the business combination deadline, 1,436,867 public shares were redeemed for approximately $14.9 million. This significantly reduced the Trust Account balance from $51.9 million (Dec 31, 2025) to $37.7 million (Mar 31, 2026).
- Extension Approval: Shareholders approved extending the deadline to consummate a business combination from January 16, 2026, to January 16, 2027. This requires monthly extension payments of $125,000 deposited into the Trust Account.
- Related Party Debt: The company issued a $600,000 promissory note to its Sponsor (Ribbon Investment Company Ltd) on March 7, 2026, to fund extension payments and working capital. $375,000 of this was deposited into the Trust Account during the quarter.
- Operating Expenses: Administrative fees decreased to $77,786 for the quarter compared to $185,401 in the same period of 2025, though the company recorded a net income due to interest earned on the Trust Account ($330,541).
Outlook, Risks, and Contingencies
- Business Combination: The company is actively pursuing the merger with DRC Medicine. The transaction involves a share exchange and the domestication of the company from the Cayman Islands to Delaware. Closing is contingent on shareholder approval, SEC effectiveness of the registration statement, and other customary conditions.
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. If a business combination is not completed by the extended deadline (January 16, 2027), the company will be required to liquidate and dissolve.
- Liquidity: The company has minimal cash outside the Trust Account ($1,878) and a working capital deficit. It relies on the Sponsor's promissory note and potential additional borrowings to fund operations and extension payments.
- Extension Payments: Subsequent to the quarter end, the company sought shareholder approval to reduce monthly extension payments from $125,000 to $50,000. As of the filing date, the meeting to approve this reduction had been adjourned to September 14, 2026.
Investor Verification Checklist
- Extension Payment Status: Verify the outcome of the shareholder meeting adjourned to September 14, 2026, regarding the reduction of monthly extension payments from $125,000 to $50,000.
- Merger Progress: Confirm the status of the S-4 registration statement and the timeline for shareholder votes required to close the DRC Medicine transaction.
- Trust Account Sufficiency: Assess whether the current Trust Account balance ($37.7M) is sufficient to cover the $2M deferred underwriting commission and potential future redemptions if the merger proceeds.
- Sponsor Solvency: Review the financial capacity of the Sponsor to honor the $600,000 promissory note and any future working capital loans if the merger faces delays.